Cancer Risk in Pulmonary Hypertension Patients

Figures & data

Table 1 Characteristics of the Study Cohort of Patients with Pulmonary Hypertension, Denmark, 1995–2017

Variable	Pulmonary Hypertension		Sub-Cohort of Patients with a Specific CTEPH Diagnosis
	N	%	N	%
Gender
Male	2847	44.9	276	45.7
Female	3488	55.1	328	54.3
Age, years
0–54	1420	22.4	123	20.4
55–64	1199	18.9	98	16.2
65–74	1686	26.6	170	28.1
75+	2030	32.0	213	35.3
Calendar period
1995–1999	968	15.3	–	–
2000–2004	1398	22.1	–	–
2005–2009	1665	26.3	97	16.1
2010–2014	1357	21.4	325	53.8
2015–2017	947	14.9	182	30.1
Hypothyroidism
No	6172	97.4	577	95.5
Yes	163	2.6	27	4.5
Hyperthyroidism
No	6098	96.3	590	97.7
Yes	237	3.7	14	2.3
Venous thromboembolism
No	5770	91.1	207	34.3
Yes	565	8.9	397	65.7
Pulmonary embolism ± deep venous thrombosis
No	5910	93.3	222	36.8
Yes	425	6.7	382	63.2
Deep venous thrombosis
No	6195	97.8	589	97.5
Yes	140	2.2	15	2.5
Chronic obstructive pulmonary disease
No	5010	79.1	433	71.7
Yes	1325	20.9	171	28.3
Interstitial lung disease
No	5941	93.8	553	91.6
Yes	394	6.2	51	8.4
HIV
No	6316	99.7	604	100
Yes	19	0.3	0	0
Portal hypertension
No	6306	99.5	–	–
Yes	29	0.5	< 5^a	–
Splenectomy
No	6317	99.7	593	98.2
Yes	18	0.3	11	1.8
Connective tissue disorders
No	5789	91.4	549	90.9
Yes	546	8.6	55	9.1
Heart failure
No	5185	81.8	481	79.6
Yes	1150	18.2	123	20.4
Total	6335	100	604	100

Notes: ^aAccording to Danish privacy rules, no cells with fewer than 5 observations may be reported.

Abbreviation: CTEPH, chronic thromboembolic pulmonary hypertension.

Figure 1 Standardized Cancer Incidence Ratios for Patients with Pulmonary Hypertension.

Abbreviations: O, observed number of cancer cases; E, expected number of cancer cases; SIR, standardized incidence ratio; CI, confidence interval.